We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Judge Says Marketing Exclusivity Begins With FDA Sign-Off on Drug
Judge Says Marketing Exclusivity Begins With FDA Sign-Off on Drug
A federal judge agreed with the FDA’s interpretation that marketing exclusivity begins with NDA approval — and not the date of controlled substance scheduling — rejecting Eisai’s bid to restore exclusivity for two of its drugs.